Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 45 | SLNB versus TAD after neoadjuvant therapy in breast cancer

Thorsten Kühn, MD, PhD, Universitätsklinikum Ulm, Ulm, Germany, discusses the evolving role of less invasive axillary staging procedures in patients with breast cancer undergoing neoadjuvant chemotherapy with initially involved lymph nodes, comparing sentinel lymph node biopsy (SLNB) with targeted axillary dissection (TAD). Data from the AXSANA (NCT04373655) study demonstrated equivalent axillary recurrence rates between these less invasive approaches and radical axillary lymph node dissection. Despite these technical differences, both procedures are safe for regional control, but disease-free survival represents the most important endpoint for comparison, as these staging procedures determine subsequent systemic and radiotherapy treatment decisions. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So while sentinel-lymph node biopsies is the standard of care for patients who undergo upfront surgery, for patients, who undergo neoadjunct chemotherapy and have involved clinically, involved lymph nodes at presentation, it was unclear whether axillary dissection could be replaced by less invasive procedures such as sentinel lymph node biopsy or TAD. So recent studies have shown equivalency between axillary lymph node dissection and less invasive procedure and the AXSANA study, which is a big study, prospective registry study that I presented at San Antonio last year, could clearly show that in terms of axillary recurrences, there was no difference between radical axillary lymph node dissection and less invasive procedures like TAD and sentinel lymph node biopsy...

So while sentinel-lymph node biopsies is the standard of care for patients who undergo upfront surgery, for patients, who undergo neoadjunct chemotherapy and have involved clinically, involved lymph nodes at presentation, it was unclear whether axillary dissection could be replaced by less invasive procedures such as sentinel lymph node biopsy or TAD. So recent studies have shown equivalency between axillary lymph node dissection and less invasive procedure and the AXSANA study, which is a big study, prospective registry study that I presented at San Antonio last year, could clearly show that in terms of axillary recurrences, there was no difference between radical axillary lymph node dissection and less invasive procedures like TAD and sentinel lymph node biopsy. Now, the new question now is, what is the best technique, sentinel-lymph node biopsies, or the additional removal of a marked lymph node that had been biopsied at the time of diagnosis? So both of these procedures are common practice, and we discussed this during my talk. There are no prospective data, there are no randomized data, Now, retrospective studies from meta-analysis have shown that the detection rate for the target lymph node biopsy is better compared to sentinel lymph node biopisy, which is about 95 % compared to 88 % for sentinel-lymph node biopsies. However, the confidence interval is wide, showing that the technique depends on experience or technical procedure, maybe. On the other hand, the false negative rates for TAD are low. They are between 5 % and 8%, whereas for sentinel lymph node biopsy, false negative rate are around 13%, according to these meta-analyses. And the question is, do these higher false negative rates translate into oncologic outcome? We could show in the AXSANA study, the study I presented in San Antonio, which will be shortly available in the Lancet Oncology, there was no difference in actual recurrence rate despite a difference in false negative rate. Therefore, in terms of regional control, both techniques are safe. However, sentinel lymph node biopsy and TAD, they are staging procedures. And as staging procedures, they DETERMINE additional treatment decisions, systemic treatment decisions and treatment decisions related to radiotherapy. So, invasive disease-free survival will be the most important endpoint to CompARE these techniques. And there is a meta-analysis back on retrospective studies showing a slight advantage for target axon resection compared to central lymph node biopsy. However, data are still scarce and these are no final results. And therefore, we introduced to the AXSANA study, which is an open prospective registry, we introduced an in-registry randomization because both of these procedures are accepted by current guidelines. So, it’s not experimental. So, we randomize within the AXSANA study to CompARE both procedures and then hopefully find out which would be the best technique to stage patients who present initially with POSITIVE lymph nodes and then CONVERT to node negativity.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.